Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 12/20 | 0.76 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497781 | 0.93 | ADORA1 (0.75) | ADORA1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL1497703 | 0.92 | ADORA1 (0.76) | ADORA1MAPT | |
| SCHEMBL1497710 | 0.89 | ADORA1 (0.74) | ADORA1DRD4MAPTDRD3KMT2A | |
| SCHEMBL1497954 | 0.89 | ADORA1 (0.72) | ADORA1DRD4MAPTKMT2ACACNA1G | |
| SCHEMBL1497964 | 0.87 | ADORA1 (0.74) | ADORA1DRD2DRD4HTR1AMAPT | |
| SCHEMBL12758720 | 0.87 | ADORA1 (1.00) | ADORA1DRD2DRD4HTR1AMAPT | |
| SCHEMBL1497843 | 0.86 | ADORA1 (0.83) | ADORA1DRD2DRD4HTR1AMAPT | |
| SCHEMBL1497821 | 0.85 | ADORA1 (0.76) | ADORA1DRD2MAPTDRD3 | |
| SCHEMBL1497774 | 0.85 | ADORA1 (0.82) | ADORA1MAPT | |
| SCHEMBL1497813 | 0.85 | ADORA1 (0.69) | ADORA1DRD2DRD4DRD3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053917-A1 | Allosteric Modulators of the A1 Adenosine Receptor | BARALDI PIER GIOVANNI | 2011-03-03 | — | — | US | claimed |
| US-7855209-B2 | Allosteric modulators of the A1 adenosine receptor | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-12-21 | — | — | US | claimed |
| EP-2081575-A2 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | King Pharmaceuticals Research and Development Inc. (US) | 2009-07-29 | — | — | EP | claimed |
| US-20080125438-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-29 | — | — | US | claimed |
| WO-2008063984-A2 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| US-20110053917-A1 | Allosteric Modulators of the A1 Adenosine Receptor | BARALDI PIER GIOVANNI | 2011-03-03 | — | — | US | disclosed |
| US-20110053917-A1 | Allosteric Modulators of the A1 Adenosine Receptor | BARALDI PIER GIOVANNI | 2011-03-03 | — | — | US | disclosed |
| US-20110053917-A1 | Allosteric Modulators of the A1 Adenosine Receptor | BARALDI PIER GIOVANNI | 2011-03-03 | — | — | US | disclosed |
| US-7897596-B2 | {2-Amino-4-[(4-(4-chlorophenyl)piperidin-1-yl)methyl]thiophen-3-yl}(4-chlorophenyl)methanone; analgesic, antidepressant; cardiac disease or disorder, neurological disease or injury, sleep disorder, epilepsy, neuropathic pain, angina | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897596-B2 | {2-Amino-4-[(4-(4-chlorophenyl)piperidin-1-yl)methyl]thiophen-3-yl}(4-chlorophenyl)methanone; analgesic, antidepressant; cardiac disease or disorder, neurological disease or injury, sleep disorder, epilepsy, neuropathic pain, angina | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897596-B2 | {2-Amino-4-[(4-(4-chlorophenyl)piperidin-1-yl)methyl]thiophen-3-yl}(4-chlorophenyl)methanone; analgesic, antidepressant; cardiac disease or disorder, neurological disease or injury, sleep disorder, epilepsy, neuropathic pain, angina | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7855209-B2 | Allosteric modulators of the A1 adenosine receptor | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20080125438-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125438-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125438-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008063984-A2 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063984-A2 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080119460-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119460-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119460-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119460-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885DRD2 770/4885DRD4 1163/4885 |
| US-20080125438-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885DRD2 770/4885DRD4 1163/4885 |
| US-20110053917-A1 | Allosteric Modulators of the A1 Adenosine Receptor | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885DRD2 845/4885DRD4 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.